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Introduction
Periodontitis (PD), the most common oral disease, is a 
destructive inﬂ   ammatory disease of the supporting 
tissues of the teeth and is caused by speciﬁ  c  micro-
organisms [1]. As a rule, PD develops through gingivitis, 
an inﬂ  ammation of the marginal periodontium. However, 
not every gingivitis develops further into PD. Both the 
amount and virulence of the microorganisms and the 
resistance factors of the host (risk factors and immune 
status) are crucial for the progression of the periodontal 
destruction (Figure 1). PD has been proposed as having 
an etiologic or modulating role in cardiovascular and 
cerebrovascular disease, diabetes, and respiratory disease 
and adverse pregnancy outcome, and several mechanisms 
have been proposed to explain or support such theories. 
Moreover, oral lesions are indicators of disease progres-
sion, and the oral cavity can be a window to overall health 
and body systems. In recent years, remarkable epi-
demiological and pathological relationships between 
periodontal diseases and rheumatic diseases, especially 
rheumatoid arthritis (RA), have been presented.
Pathogenesis of periodontal diseases
Chronic, plaque-associated inﬂ  ammation of the perio-
dontium is among the most common oral diseases and 
has a prevalence of 80% to 90% [1], resulting in soft and 
hard periodontal tissue destruction and ultimately in 
tooth loss [2]. Both the amount and virulence of the 
microorganisms and the resistance factors of the host 
(risk factors and immune status) are crucial for the 
initiation and progression of the periodontal destruction 
[3]. Besides detailed concepts about microbiological, 
molecular, and cellular mechanisms, which determine 
the strength and balance of the cellular and humoral host 
response in tissues, it became apparent that a complex 
and primarily endogenous periodontal microﬂ  ora  is 
responsible for disease initiation and progression.
Bacterial oral infection
PD is to be understood as an opportunistic infection [4]. 
It results directly in tissue injury or provokes excessive, 
autodestructive inﬂ  ammatory responses, depending on 
the pathogenicity of the agents or the performance of the 
immune defense. In particular, Gram-negative anaerobic 
bacteria, which form a bacterial plaque bioﬁ  lm on the 
tooth surface, initiate this tissue-destroying process [5]. 
Among a complex and still largely unknown microﬂ  ora, 
about 20 bacteria species, which live in the subgingival 
environment, have been identiﬁ   ed as periodontal 
pathogens and are linked to several forms of PD. Th  e  best 
analyzed of these bacteria are Porphyromonas gingivalis, 
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Biofi  lm infection
In the periodontal pocket of periodontal disease, there 
exists a condition in which periodontopathic bacteria 
form a ﬁ  lm-like colony by adherence and aggregation [7]. 
After a few hours, resident microorganisms – most of 
which are mostly Gram-positive – stick to the mem-
branaceous layer of the smooth surface of the teeth 
(pellicle layer), which settles within minutes up to a few 
hours after thorough mechanical tooth cleaning. By 
means of ﬁ  mbriae, pili, and so-called glycocalyx, Gram-
negative bacteria can attach to those microorganisms [8]. 
A complex and extremely resistant bioﬁ  lm with a decisive 
evolutionary advantage for the bacteria develops. Th  ey 
can cooperate metabolically [8], and because of the 
complexity and subgingival location, the bacteria are 
protected from immunologic defense mechanisms of the 
host as well as from antibiotic agents. Th  e  enhancement 
of the bacterial pathogenicity is a result thereof [8]. 
Continuous stimulation by bacteria inﬂ  icts injury within 
the gingiva, destroys the local immune system, and 
activates osteoclasts in the tissue, so that the PD can 
progress [9].
Virulence factors
Besides the ability to form bioﬁ  lms, the synthesis of toxic 
substances is among the most important characteristics 
of dental pathogenic bacteria. Enzymes have a direct 
tissue-destroying eﬀ   ect (neutral phosphatases and 
collagenases). Leucotoxins and immunoglobulin-splitting 
substances elude defense mechanisms [10]. Moreover, 
osteoclast-activating alkaline and acid phosphatases lead 
indirectly to the loss of the periodontal attachment 
apparatus. Lipopolysaccharides (LPSs) and proteo  gly  cans, 
which are both part of the cell wall of Gram-negative 
bacteria, play a key role in activating the immune system 
with the release of diverse cytokines, subsequently 
causing alveolar bone resorption.
The two phases of the immune response - 
the critical pathway
Th   e pathogenetic model of the critical pathway assumes 
the simple cause-and-eﬀ   ect principle and permits a 
diﬀ   erentiated view of the processes of the marginal 
development of PD. According to this model, there are 
two phases [11].
First phase: initial immune response
Th   rough the junctional epithelium, which adheres to the 
tooth surface, a constant immunologic interaction 
between periodontal-pathogenic bacteria and the cells of 
the immune system takes place [10]. Bacteria release 
metabolites and toxins and thereby activate the immune 
system. LPS is one of the strongest activators of immuno-
logic inﬂ   ammatory processes [10,12]. Apart from the 
formation of integrin ICAM-1 (intercellular adhesion 
molecule-1), numerous proinﬂ  ammatory and inﬂ  amma-
tory cytokines such as interleukin-1-beta (IL-1β) as well 
as IL-6, IL-8, IL-1, and tumor necrosis factor-alpha 
(TNF-α) [13] are involved in this process. In this way, the 
path of the neutrophil granulocytes via leucodiapedesis 
through the endothelium to the inﬂ  ammatory center is 
established [10]. Th  ere, pathogenic bacteria, which are 
opsonized by complement factors (C3b and C4b) and 
immunoglobulins (IgG1 and IgG2), are phagocytosed 
[14]. Th  is early inﬂ  ammatory response to the bioﬁ  lm is 
dominated by polymorph nuclear leucocytes (PMNLs), 
which have a modulatory eﬀ  ect on T and B lymphocytes 
and which increasingly penetrate the tissue [15]. An 
increased secretion of gingival sulcus ﬂ  uid leads to the 
washout of proinﬂ  ammatory mediators and the recruit-
ment of inﬂ   ammatory cells from the tissue. Together 
with immunoglobulins, PMNLs form an eﬀ  ective defense 
bank against pathogenic microorganisms [11]. If the 
microbial attack is successfully and suﬃ   ciently embanked 
in this ﬁ  rst phase, the inﬂ  ammation is – according to the 
model of the critical pathway – restricted to the marginal 
gingiva (resulting in gingivitis) [11]. Th   e second phase of 
the immune response is activated if the described defense 
mechanisms are insuﬃ   cient.
Second phase of the immune reaction
Current data show that PD develops preferably in disposed 
persons with an abnormal inﬂ  ammatory immune reaction 
to microbial plaque. Monocytes or macrophages or both 
become active as an unspeciﬁ  c immune response [16]. 
Histologically, the longer-lasting inﬂ  ammation manifests 
itself in the conversion of the junctional epithelium into 
Figure 1. Severe periodontitis with loss of periodontal 
attachment and alveolar bone.
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by its increased prolifera  tion rate in the basal area and an 
increased permeability for larger molecules. Because of 
the stimulation of the CD14 receptors by LPS complex 
formation, macrophages secrete the prostaglandin E2 
(PgE2) and the proinﬂ   am  matory cytokines IL-1β and 
TNF-α, which convey the periodontal bone absorption. 
Matrix metalloproteinases (MMPs) participate in the 
des  truction of the extracellular matrix [12]. Furthermore, 
secondary inﬂ   ammatory media  tors (for example, the 
platelet-activated factor and biogenic amines [bradykinin 
and histamin] [16]) support the adhesion of neutrophil 
granulocytes to endothelic cells by endothelial expression 
of adhesion molecules [12]. IL-1β and PgE2 both have an 
inhibiting eﬀ  ect on the collagen synthesis [12]. PgE2 leads 
to vasodilation, bone atrophy, and edema formation [12]. 
B and T cells and plasma cells are to be found in the 
inﬂ  ammatory  inﬁ   ltrate and gingival sulcus ﬂ  uid, 
respectively. Most of the plasma cells form 
immunoglobulins of the type IgG (approxi  mately 60% to 
80%). Signiﬁ   cantly fewer of those formed are IgAs 
(approximately 10% to 40%), and only a few are IgMs 
[17]. Th  e local antibody synthesis produces antibodies 
that are diverse in quantity and speciﬁ  city. Th  ese  antibodies 
can be more frequently local than systemic [17].
Rheumatic diseases such as rheumatoid arthritis 
and periodontitis
Many recent studies have identiﬁ  ed statistically signiﬁ  -
cant associations between established PD and rheumatic 
diseases. In particular, RA as a chronic inﬂ  ammatory 
joint disease shows numerous characteristics and patho-
genetic processes that have similarities to PD. RA and its 
relationship to PD are the best-studied topics, and there 
are numerous publications in this regard. Th  erefore,  this 
review focuses on this disease. Interesting and important 
results that describe the importance of microcirculation, 
osteoporosis, and other common risk factors in respect 
to the relationship between the rheumatic diseases such 
as RA and PD are expected to appear in the future.
Association studies in rheumatoid arthritis 
and periodontitis
It has been reported that patients with longstanding 
active RA have a signiﬁ  cantly increased incidence of PD 
when compared with healthy subjects [18-20] and that 
patients with PD have a higher prevalence of RA than 
patients without PD [21]. de Pablo and colleagues [22], 
using data from the Th   ird National Health and Nutrition 
Examination Survey (NHANES III), show a signiﬁ  cant 
association between RA and PD in the US population. In 
patients with RA, a signiﬁ  cant correlation in teeth loss 
and alveolar bone loss was found, and this may well 
represent various aspects of periodontal health [23].
Role of oral infections and immune response
Successful treatment of RA with antibiotics against 
bacterial anaerobic infections points to the involvement 
of bacteria in the etiopathogenesis of RA [24]. Th  e 
hypothesis that oral infections play a role in RA patho-
genesis may be supported by the detection of bacterial 
DNA of anaerobes and high antibody titers against these 
bacteria in both the serum and the synovial ﬂ  uid of RA 
patients in the early and later stages of the disease [25]. 
Th  e highly pathogenic bacteria of the oral ﬂ  ora  can 
maintain a chronic bacteremia that may damage distant 
organs (joints and endocardium) [26]. Periodontal patho-
gens, as P. gingivalis, have the ability to impair epithelium 
integrity, invade human endothelium cells, and inﬂ  uence 
both transcription and protein synthesis [27]. By these 
means, periodontal pathogenes have a direct systemic 
access to the blood circulation [28]. Examinations of 
patients with RA show an increased number of speciﬁ  c 
antibodies and the DNA of these bacteria in the blood 
and synovial liquid [29]. Recently, it was shown that 
P. gingivalis is able to invade primary human chondro-
cytes that were isolated from knee joints and to induce 
cellular eﬀ  ects [30]. As a consequence of this invasion, 
P. gingivalis delayed cell cycle progression and increased 
cell apop  tosis in these chondroncytes [30].
P. gingivalis and gingipains
P. gingivalis produces arginine-speciﬁ  c (gingipain R) and 
lysine-speciﬁ  c (gingipain K) cystein endopeptidase [24], 
which play a role in bacterial housekeeping and infection, 
including amino acid uptake from host proteins and 
ﬁ  mbriae maturation [31,32]. Gingipains are proteolytic 
enzymes [32] responsible for the expression of the viru-
lence. Proteinases such as MMP-1, MMP-3, and MMP-9 
are activated and extracellular matrix host proteins such 
as laminin, ﬁ   bronectin, and collagen are degraded by 
P. gingivalis gingipains [33]. Furthermore, gingipains are 
responsible for an increased vascular permeability and 
for the degradation of complement factors [33].
P. gingivalis and the enzyme peptidylarginine deiminase
P. gingivalis is currently the only known bacterium with 
expression of peptidyl arginine deiminase (PAD), which 
represents an important pathogenic factor of RA [20,34]. 
Th  e enzymatic deimination of arginine residuals to 
citrulline through the enzyme PAD is a form of post-
translational protein modiﬁ  cation [35]. Th  e  consequence 
is a modiﬁ  cation of the structu    re of the protein, by which 
its biochemical and antigen characteristics are changed. 
However, the PAD expressed by P.  gingivalis is not 
entirely homologue to human PAD but leads to an 
irreversible, post-translational conversion of arginine to 
citrulline [20,35]. So far, citrullination has been found 
particularly in proteins of the cytoskeleton (for example, 
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apoptosis. Diseases like RA result in the (patho)physio-
logical citrullination of structure proteins and in an 
increased accumulation of citrullinated proteins (for 
example, mutated citrullinated vimentin) [26]. Th  e 
reduced immunotolerance of these patients to citrulli-
nated proteins seems to be a key problem, so that – 
especially for RAs of high severity – an increased 
formation of autoantibodies develops [26]. For P. gingivalis, 
the by-product ammoniac serves as a neutralizer of the 
acid milieu and thereby ensures the growth of the 
bacterium [34]. Interestingly, patients with PD show a 
high concentration of ammonia in the sulcus ﬂ  uid [34]. 
Possibly, periodontal infections with pathogens such as 
P. gingivalis in association with a genetic predisposition 
support inﬂ   ammatory diseases like RA or have an 
immuno regulating  eﬀ  ect on the course of the disease or 
both [10,20]. In this context, the P.  gingivalis titer in 
patients with RA correlated signiﬁ  cantly with the concen-
tration of anti-citrullinated protein/peptide antibody 
(ACPA) [10,20]. It is thus hypothesized that in a genetically 
susceptible (shared epitope-positive) individual, such 
citrullinated peptides may interrupt tolerance to endoge-
nous citrullinated antigens, resulting in the generation of 
an immune response to citrullinated self-antigens. 
Hitchon and colleagues [36] reported an association 
between immune responses to the oral pathogen 
P. gingivalis and the presence of ACPA in a population 
with a high background prevalence of RA-predisposing 
HLA-DRB1 alleles. Th  is gene-environment interaction 
may result in breaking self-tolerance to citrullinated 
antigens or ampliﬁ  cation of these autoimmune responses 
or both and may ultimately lead to the development of 
RA [36].
P. gingivalis and the rheumatoid factor
Th   e rheumatoid factor (RF) has been found in RA and in 
other chronic inﬂ  ammation diseases, including PD [20]. 
Th   e RF could be veriﬁ  ed in the gingiva, in the subgingival 
plaque, and in the serum of patients with PD [34]. 
Seropositive patients with PD showed increased titers of 
IgG and IgM antibodies against oral microorganisms 
when compared with seronegative patients with PD [34]. 
Th  e RF of seropositive patients shows a cross-reaction 
with oral bacterial epitopes [37]. Th  e P.  gingivalis 
proteinase is responsible for the epitope development in 
the RF-Fc region. Th  e proteinases are regarded as 
important virulence factors since they make the growth 
of P. gingivalis possible and lead to the degradation of the 
host tissue [38]. Bonagura and colleagues [39] identiﬁ  ed 
the lysine and arginine amino acid sequences for these Fc 
regions of the IgG molecule. Since P. gingivalis decom-
poses lysine and arginine in particular and the IgG3 CH2 
and CH3 domains are processed by the P.  gingivalis 
proteinase, they take over a key function in the RF 
production of rheumatoid cells [40]. A current study 
(n = 69) of patients with RA evaluated the prevalence and 
severity of PD and their relationship to RA disease 
activity and severity [41]. Patients with osteoarthritis 
(OA) served as controls (n  =  35) [41]. PD was more 
common and severe in patients with RA when compared 
with patients with OA [41]. Th   ough apparently unrelated 
to disease activity, the presence itself of these auto-
antibodies does seem to be hi    ghly relevant in association 
to disease pathogenesis in RA and the occurrence of poor 
outcomes.
Periodontitis, rheumatoid arthritis, and genetic factors
In 1987, a successful demonstration of the connection 
between HLA-DR4 and rapidly progressive periodontitis 
(RPP) by speciﬁ  c typing of the HLA gene loci HLA-A, 
HLA-B, HLA-C, and HLA-D was achieved. In that study, 
a DR4 frequency of 80% in patients with RPP as opposed 
to 38% in the control group was observed [42]. Another 
study [43] conﬁ  rmed these results by an examination of 
the DRB1*04 alleles that code HLA-DR4. In patients with 
RPP, a signiﬁ  cantly higher frequency (42%) of one of the 
DRB1 subtypes *0401, *0404, *0405, or *0408 could be 
detected, whereas the control group showed a frequency 
of these subtypes to be only 7%. Th   ese DRB1 subtypes are 
part of the so-called shared epitope genotypes, which also 
play a role in other inﬂ  ammatory diseases like RA [26].
Superantigens and heat shock proteins
Heat-resistant, hydrophilic molecules with a molecular 
weight of 24 to 30 kDa are referred to as superantigens. 
Th  ey are able to virtually glue together T-cell receptors 
(TCRs) and major histocompatibility complex II mole-
cules [44], which trigger a permanent signal in T cells. 
Th  e region V beta (VβV) has been identiﬁ   ed as the 
binding position for superantigens and is located in the 
variable part of the beta chain of the TCR. TCRs of the 
Vβ gene (Vβ 6, 8, 14, and 17) are more frequent in 
patients with RA than in the control groups [45]. Th  ese 
superantigens of RA can be inﬂ  uenced by oral bacteria, 
although the P. intermedia stimulates the expression of 
Vβ 8 and Vβ 17 genes in CD4 (+) T cells, and both 
bacteria P. gingivalis and P. intermedia can also increase 
the expression of Vβ 6 and Vβ 8 [46].
Heat shock proteins (HSPs) protect the cell from stress 
by reversibly interacting with abnormal proteins and 
peptides and by participating in their backfolding and 
decomposition. Furthermore, HSPs ful  ﬁ  ll a function in 
the hereditary and acquired immunity and are associated 
with the pathogenesis of RA [47].
In the serum of patients with RA, high levels of oral 
bacterial HSP were found. Seventy-kilodalton Prevotella 
melaninogenica HSP and P.  intermedia HSP have also 
Detert et al. Arthritis Research & Therapy 2010, 12:218 
http://arthritis-research.com/content/12/5/218
Page 4 of 7been identiﬁ   ed in periodontal disease [24]. However, 
HSP 70 antibodies are also found in the synovium of 
patients with RA and occur in the synovialis if the HSP 
70 expression is triggered by speciﬁ  c stress factors (for 
example, heat, trauma, endotoxins, and anti-inﬂ  amma-
tory drugs) and by proinﬂ  ammatory cytokines (TNF-α, 
IL-1, and IL-6) [24]. Th   erefore, superantigens and HSP in 
patients with RA are not speciﬁ  c to oral bacteria [24].
Autoantigens
Th   e citrullinated form of the α-enolase is an autoantigen 
that plays a role in the glycolysis. α-Enolase operates as a 
receptor and activator of plasminogen, as an HSP, and as 
a Myc-binding protein [26]. Th  e citrullinated α-enolase 
has been detected together with other citrullinated 
antigens in the synovial tissue of patients with early RA 
[26]. However, the ﬁ  nding of a speciﬁ  city of 97.1% in this 
cohort is remarkable. Lundberg and colleagues [27] 
identiﬁ  ed an immunodominant epitope of the citrulli-
nated α-enolase. Th   e data on the sequence similarity and 
cross-reactivity let us assume that this immunodominant 
epitope of the citrulli  nated α-enolase plays a role in the 
primary autoimmunity of a subgroup of RA patients with 
bacterial infections, especially P. gingivalis [20,27].
It is well known that immunoglobulins of the class IgG 
act as antigens. Interestingly, IgG is glycolized diﬀ  erently 
in patients with RA. In 60% of the patients but not in 
healthy control groups matched by age, the terminal 
galactose is missing in the carbohydrate groups of the Fc 
part. Anti-agalactosyl IgG antibodies (CARF) showed a 
slightly higher sensitivity of 73.9% but a speciﬁ  city as low 
as that for RF. Th   is lack of terminal galactose is associated 
with a poor prognosis in the course of the disease [48]. 
Under these conditions, the saccharolytic bacterium 
P. melaninogenica is able to bind at the Fc region of the 
IgG molecule and to metabolize galactose with its 
enzyme [49]. Variations in the composition of the sugar 
moiety can inﬂ  uence antibody activity in autoimmune 
disorders. Furthermore, there are bacteria (Escherichia 
coli) that are inhibited by galactose (Gal) or N-acetyl-
galactosamines (GalNAc) and other carbohydrates [50].
Th   e pathogenic periodontal bacteria produce enzymes 
(collagenases, hyaluronidases, neuraminidases, and 
others) that degenerate the intercellular matrix and the 
collagenous skeleton, thereby facilitating the inﬁ  ltration 
of further microorganisms into the tissue [38]. In patients 
with RA, the presence of autoantibodies against collagen 
II (CII), a main component of the hyaline cartilage, has 
been veriﬁ  ed [51]. P. gingivalis expresses a lysine-speciﬁ  c 
proteinase, shows collagenase activity, and reduces all 
collagen molecules except from those for CII [52]. Lysine 
in position 270 of CII 263 to 370 can be hydroxylized and 
further on glycolized to monosaccharides or disaccha-
rides (for example, with a beta-D-galactopyranosyl or 
with an alpha-glycopyranosyl-(1,2)-beta-galactopyranosyl 
residue).
T helper 17 cells and interleukin-17
Th  e role of the T helper 17 (Th  17) cells in the host 
defense is not completely known. It was able to be shown 
that IL-17 stimulates the generation and mobilization of 
neutrophils and plays an important role in the defense of 
extracellular bacteria [53]. Th  17 cells and IL-17 play an 
important role in the pathogenesis of RA. On the other 
hand, Th   17 cells are also present in chronic periodontal 
disease [54]. IL-17 can be found in periodontal lesions 
and potentially plays a role in the etiopathogenesis of 
periodontal disease. Th  e P. gingivalis antigen stimulates 
the T cells to express IL-17 [54].
Metallomatrix proteinases
Under a clinically healthy gingival situation, the con-
tinuous cellular composition and decomposition pro-
cesses in the periodontium are balanced, so that collagen 
decomposing MMP and tissue inhibitors of MMP 
(TIMPs), for example, are always to be found. In PD, 
TIMPs are overbalanced in favor of the MMPs, which 
consequently have an increased active concentration. A 
key enzyme for the tissue destruction in the context of 
PD, MMP-8 in its active form decomposes ﬁ  brillar 
collagen structures and also is associated with alveolar 
bone destruction [12,55]. Consequently, the detection of 
mediators such as MMP-8 in the gingival sulcus ﬂ  uid 
may be a method to monitor inﬂ  ammatory activities, and 
this adds to classical periodontal diagnostics (probing 
depths, clinical attachment level, and bleeding on 
probing). A recent study showed lower MMP-8 levels in 
the healthy control group than in the RA group with 
gingivitis, in the RA group with PD, or in the systemically 
healthy PD group (P <0.05) [55]. In contrast, MMP-13 
levels were similar in all groups (P >0.05). RA patients 
with gingivitis or PD had similar MMP-8, MMP-13, and 
TIMP-1 levels as did the systemic healthy control group 
(P >0.05). Th  is study indicates that the simultaneous 
appearance of RA and PD has no inﬂ   uence on the 
investigated parameters. Increased MMP-8 levels in the 
gingival sulcus ﬂ   uid can be found in periodontal 
inﬂ  ammation. Th  e long-term application of gluco  corti-
coids and nonsteroidal anti-inﬂ  ammatory drugs causes 
similar high MMP-8 and MMP-13 levels in RA patients 
and systemic healthy probands and possibly results in an 
overproduction of those enzymes.
Risk factors in periodontitis or rheumatoid arthritis 
or both
Th   e clinical appearance of PD (Figure 1) and RA can be 
inﬂ   uenced by congenital as well as acquired factors, 
which can increase the probability of the development 
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pathogenetic point of view, risk factors other than 
pathogenic bacteria and oral hygiene play a crucial role. 
Th  ese risk factors can inﬂ  uence every sub-step of the 
pathogenesis, and this explains the individually diﬀ  erent 
manifestations of the disease [3]. Th  e individual risk 
factors such as age, gender, body mass, and genetic 
factors (IL-1β polymorphism and HLA gene associations) 
are the focus of attention. Other exogenic risk factors 
such as nutritive factors, socioeconomic status, psycho-
logical factors (for example, stress), and lifestyle (cigarette 
smoking and alcohol consumption) as well as systemic 
diseases may inﬂ   uence the pathogenesis [56,57]. 
However, it has also been known for some years now that 
patients with PD not only suﬀ  er from local loss of the 
connective tissue and the hard tissue but also have an 
increased risk of developing systemic diseases [58]. Th  is 
interrelation is referred to as ‘periodontal medicine’.
Smoking
Th  e best documented environmental factor that contri-
butes to RA susceptibility is smoking. Importantly, 
smoking appears to contribute to disease susceptibility 
only in individuals who develop autoantibody-positive RA 
characterized by the presence of ACPAs. Th  ere is a 
clustering of RA risk associated with smoking, presence of 
shared epitope alleles and the presence of ACPA [58]. 
Hitchon and colleagues [36] tried to determine whether 
oral hygiene and smoking are associated with RA, ACPA, 
and immune responses to P. gingivalis. It is known that 
smoking and poor oral health habits both increase the risk 
of PD [36]. Smoking is a risk factor for PD possibly through 
the eﬀ  ects of nicotine on inﬂ  ammatory cytokine proﬁ  les 
[59] and MMP-3 activity [60] or potentially even through 
direct eﬀ  ects on P. gingivalis gene expression. Hitchon and 
colleagues [36] did ﬁ  nd a high prevalence of both smoking 
and poor oral health habits in the study population on the 
basis of self-report questionnaire data; however, they could 
not deﬁ  ne a clear association between these factors and 
the presence of either RA or ACPA.
Conclusions
We conclude that there is some evidence for the relation-
ship between the presence of PD and the development of 
RA. Th  e existence of an inﬂ  ammatory systemic disease 
may promote PD in both its emergence and progress. 
Periodontal pathogens have direct systemic access to the 
blood circulation. Th   erefore, treatment with antibiotics in 
patients with RA can be eﬀ  ective.  Th  e enzyme PAD 
represents an important pathogenetic factor for RA. P. 
gingivalis is currently the only known bacterium with 
expression of PAD and plays a role in the humoral immune 
response and in the presence of APCA in patients with 
RA. Oral hygiene and smoking represent environmental 
factors inﬂ  uencing the risk for the develop  ment of RA. 
Other risk factors (for example, nutritive factors, stress, 
and lifestyle factors) should also be examined in the future 
with regard to their relation  ship to PD and RA. Further 
basic and clinical studies are needed. In particular, 
longitudinal studies are needed in order to clarify the 
temporal relationship between PD and RA. Th  ese  studies 
will need to include high numbers of patients but a low 
number of confounding factors in order to derive ﬁ  rm 
conclusions. For clinical studies, it is necessary to create a 
network of cooperation with rheumatologists and dentists.
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